PM Narendra Modi’s visit serves great inspiration to our team: Bharat Biotech

Bharat Biotech, a leader in pandemic vaccines, also said we are truly honoured by this recognition.

Mr Modi's visit serves as a great inspiration to our team, and further reinforces our commitment towards scientific discovery, solving public health issues, and the nation’s fight against COVID-19, Bharat Biotech said in a release here.

COVAXIN™ India’s first indigenous vaccine with the Phase 3 clinical trial underway, is the first, largest, and the only efficacy trial in the developing world, involving a large number of volunteers across 25 sites.

The COVAXIN™ phase III trial is being conducted across India in 26,000 participants. The vaccine will be produced in the only-of-its-kind Biosafety Level 3 production facility in the world.

We take this opportunity to thank the Government of India, Regulators, our vaccine development partners, medical fraternity, medical investigators including hospitals for their relentless assistance and cooperation in the development of vaccines, also phase 3 clinical trials for COVAXIN, Hyderabad-based vaccine maker said.

'We greatly appreciate every volunteer who has come forward for the trial thus far and we thank you for your service to the nation.

Bharat Biotech reiterates our commitment towards developing a safe and efficacious vaccine for all', the release added.